Safety, Reactogenicity & Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Administered Intramuscularly According to a Schedule of 0, 1 Month, to Healthy Adults Aged 18 to 50 Years.
Phase of Trial: Phase I/II
Latest Information Update: 02 Jan 2019
At a glance
- Drugs GSK 692342 (Primary) ; AS01A; AS02
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 14 Nov 2011 Actual end date changed from Mar 2007 to Dec 2009 as reported by ClinicalTrials.gov.
- 27 Oct 2008 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History